Article
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
Blood - 3 Apr 2014
Rossi Davide, Khiabanian Hossein, Spina Valeria, Ciardullo Carmela, Bruscaggin Alessio, Famà Rosella, Rasi Silvia, Monti Sara, Deambrogi Clara, De Paoli Lorenzo, Wang Jiguang, Gattei Valter, Guarini Anna, Foà Robin, Rabadan Raul, Gaidano Gianluca
Abstract excerpt
TP53 mutations are strong predictors of poor survival and refractoriness in chronic lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical information on TP53 mutations is limited to lesions represented in >20% leukemic cells. Here, we tested the clinical impact and prediction of chemorefractoriness of very small TP53 mutated subclones. The TP53 gene underwent ultra-deep-next...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.